MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/bcp.15464

Медицинская библиотека · British journal of clinical pharmacology · 2022

Effectiveness and safety of intracranial events associated with the use of direct oral anticoagulants for atrial fibrillation: A systematic review and meta-analysis of 92 studies.

Archontakis-Barakakis Paraschos, Li Weijia, Kalaitzoglou Dimitrios, Tzelves Lazaros, Manolopoulos Apostolos, Giannopoulos Stefanos, Giamouzis Grigorios, Giannakoulas George, Batsidis Apostolos, Palaiodimos Leonidas, Ntaios George, Lip Gregory Y H, Kokkinidis Damianos G

СтатьяМетаанализСистематический обзорПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

AIMS: Observational studies have investigated the effectiveness and safety of direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs) used in nonvalvular atrial fibrillation. We performed a systematic review and meta-analysis assessing the risk of ischaemic stroke, thromboembolism (TE) and intracranial haemorrhage (ICH) associated with the use of DOACs and VKAs.

METHODS

Medline and Embase were systematically searched until April 2021. Observational studies were gathered and hazard ratios (HRs) with 95% confidence intervals (CI) were extracted. Subgroup analyses based on DOAC doses, history of chronic kidney disease, stroke, exposure to VKA, age and sex were performed. A random-effects model was used.

RESULTS

We included 92 studies and performed 107 comparisons. Apixaban was associated with lower risk of stroke (HR: 0.82, 95% CI: 0.68-0.99) compared to dabigatran. Rivaroxaban was associated with lower risk of stroke (HR: 0.90, 95% CI: 0.83-0.98) compared to VKA. Dabigatran (HR: 0.85, 95% CI: 0.80-0.91), rivaroxaban (HR: 0.83, 95% CI: 0.77-0.89) and apixaban (HR: 0.75, 95% CI: 0.65-0.86) were associated with lower risk for TE/stroke compared to VKA. Apixaban (HR: 1.32, 95% CI: 1.03-1.68) and rivaroxaban (HR: 1.58, 95% CI: 1.31-1.89) were associated with higher risk of ICH compared to dabigatran. Dabigatran (HR: 0.48, 95% CI: 0.44-0.52), apixaban (HR: 0.60, 95% CI: 0.49-0.73) and rivaroxaban (HR: 0.73, 95% CI: 0.65-0.81) were associated with lower risk of ICH compared to VKA.

CONCLUSION

Our study demonstrated significant differences in the risk of ischaemic stroke, TE/stroke and ICH associated with individual DOACs compared to both other DOACs and VKA.

Для цитирования: Archontakis-Barakakis Paraschos, Li Weijia, Kalaitzoglou Dimitrios, Tzelves Lazaros, Manolopoulos Apostolos, Giannopoulos Stefanos, Giamouzis Grigorios, Giannakoulas George, Batsidis Apostolos, Palaiodimos Leonidas, Ntaios George, Lip Gregory Y H, Kokkinidis Damianos G. Effectiveness and safety of intracranial events associated with the use of direct oral anticoagulants for atrial fibrillation: A systematic review and meta-analysis of 92 studies.. British journal of clinical pharmacology. 2022. DOI: 10.1111/bcp.15464.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.